KINO Studios Secures Over $2M In Pre-seed Funding
Innovative LA-based Film Tech Start-up Draws Investment from Top Industry Players.
High-profile contributors to the round included Sequoia Capital's Scout program, Blockchain Founders Fund, Slow Ventures, Metaweb Ventures, Genius Ventures, The Near Protocol, and an assortment of industry experts and angel investors. KINO's mission is to equip filmmakers with state-of-the-art tools to engage, create, and monetize their content even before it hits the screens, addressing a massive gap in the market.
"During the production cycle, film and TV shows currently do zero marketing or product market fit," states co-founder
With credits to his name like projects with
"The film and television creator economy is drastically changing— has drastically changed with the rise of the internet, and crucially social media apps like Instagram and
Already, KINO captivates over a million film aficionados monthly. Its avant-garde app, available for early access on the App Store, offers a plethora of features from celebrity live-streams and exclusive behind-the-scenes content to authentic movie merchandise and exclusive red-carpet event tickets.
With a powerful lineup of advisors and partners from industry giants like Netflix, Disney, HBO, and more, KINO is poised to make waves.
"The film and TV industry has often lagged in tech adoption. KINO's groundbreaking approach bridges this gap, tapping into the creator economy and redefining audience engagement. We're thrilled to back their vision." -
ABOUT KINO STUDIO
ABOUT KINO'S FOUNDERS
View original content to download multimedia:https://www.prnewswire.com/news-releases/kino-studios-secures-over-2m-in-pre-seed-funding-301953017.html
SOURCE KINO
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- THE WEEKND KICKS OFF EUROPEAN LEG OF RECORD-BREAKING AFTER HOURS TIL DAWN TOUR WITH TWO SOLD-OUT SHOWS AT COPENHAGEN'S PARKEN STADIUM
- 10,000 Backpacks Donated for Pack the Mack Giveaway
- CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Sequoia CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share